Barbara Burtness

Featured in: Favicon

nature.com Favicon

wiley.com

mdpi.com

jamanetwork.com Favicon

thelancet.com Favicon

newswise.com Favicon

healio.com Favicon

newsbreak.com Favicon

ascopubs.org Favicon

tmc.edu + 6 more

Articles

Dr Burtness on Subgroup Outcomes for Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer

Jun 14, 2024 | onclive.com | Barbara Burtness

CommentaryVideoJune 14, 2024Author(s):Barbara Burtness, MD, discusses findings from a subgroup analysis from the phase 2 E3311 trial in HPV-associated oropharynx cancer.
Reducing Radiation After Surgery Prolongs Survival

May 29, 2024 | newswise.com | Barbara Burtness

BYLINE: Michael Masciadrelli Newswise — Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study. Less than the standard doses of post-operative radiation therapy is safe and effective and reduces side effects, researchers say, resulting in very high survival rates —marking a significant advancement in head and neck cancer care.
New Research and Treatment Advances From Yale Canc

May 13, 2024 | newswise.com | Eric S. Winer |Michael Cecchini |Roy S. Herbst |Barbara Burtness

Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
Expert Discusses Safety of Toripalimab in Advanced Nasopharyngeal Carcinoma

Jan 24, 2024 | cancernetwork.com | Barbara Burtness

The safety profile of toripalimab-tpzi (Loqtorzi) in patients with metastatic or locally advanced nasopharyngeal carcinoma (NPC) appear to be comparable with prior reports of other PD-1 inhibitors, said Barbara Burtness, MD.
Toripalimab Yields ‘Striking’ PFS Improvement in Nasopharyngeal Carcinoma

Jan 19, 2024 | cancernetwork.com | Barbara Burtness

“Solid” progression-free survival (PFS) and overall survival (OS) data with toripalimab-tpzi (Loqtorzi) support the role of PD-1 inhibition in the frontline treatment of those with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to Barbara Burtness, MD.
Researchers develop a new way to classify HPV-associated head and neck cancers

Jul 31, 2023 | newswise.com | Barbara Burtness

Newswise — Human papillomavirus (HPV) has been linked to a significant increase in cancers of the throat and tonsils over the past few decades; this is projected to become the most common form of head and neck cancer by 2030. But a major limitation to reducing treatment intensity is the inability to correctly identify the patients whose HPV-related cancers will be the most responsive to treatment.
Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer

May 2, 2023 | newsbreak.com | Barbara Burtness

I was sued by my co-workers after announcing I’d won a $105m lottery – but there was an even stranger twist
Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer

May 2, 2023 | onclive.com | Barbara Burtness

Barbara Burtness, MD, professor of medicine, Medical Oncology, chief translational research officer, chief, Head and Neck Cancers/Sarcoma, co-leader, Developmental Therapeutics, associate cancer center director for translational research, Yale Cancer Center, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma (HNSCC) and lung cancer.